Clinical Trial Update: Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating eculizumab to enable renal transplantation in patients with a history of catastrophic antiphospholipid antibody syndrome (APS).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antiphospholipid Antibody Syndrome
• End-stage Renal Disease

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Johns Hopkins University | Conditions: Antiphospholipid Antibody Syndrome, End Stage Renal Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-10-26